Customized molecular diagnostics of bacterial bloodstream infections for carbapenem resistance: A convenient and affordable approach.

The acute crisis of carbapenem resistance impedes the empirical use of carbapenems in medical emergencies, especially, bloodstream infections. Carbapenemase-producing carbapenem-resistant organisms (CP-CROs) attribute high case-fatality, necessitating rapid diagnostics to initiate early targeted antibiotics. Expensive diagnostics are the major driver of antibiotic misuse, neglecting evidence-based treatment in India. One in-house molecular diagnostics assay was customized for rapid detection of CP-CROs using positive blood-culture (BC) broths at a low-cost. The assay was validated using a known-set of isolates and evaluated on positive BC broths. DNA was extracted from positive BC broths using a modified alkali-wash/heat-lysis method. One end-point multiplex-PCR was customized targeting five carbapenemases (KPC, NDM, VIM, OXA-48-, and OXA-23-type) with 16S-rDNA as internal extraction control. Carbapenem resistance due to other carbapenemases, efflux-pump activity, and loss of porins was not under the scope of the assay. Promising analytical performances (sensitivity and specificity, >90%; kappa = 0.87), encouraged to assess diagnostic value, qualified the assay for the WHO minimal requirements (both≥95%) for a multiplex-PCR. Higher LR+ (>10) and lower LR- (<0.1) indicate a good diagnostic tool for ruling in or ruling out CRO bloodstream infections. Inclusion of OXA-23-type improved assay positivity. Multiple carbapenemases were detected in>30% of samples. Good concordance was found (kappa = 0.91) with twenty-six discrepant results. The results were available in 3 hours. The running cost of the assay was US$10 per sample. Fast and reliable detection of carbapenemase(s) allows clinicians and infection-control practitioners to execute early-directed therapy and containment measures. This convenient approach facilitates implementing the assay in resource-limited healthcare settings.

[1]  Surojit Das The crisis of carbapenemase-mediated carbapenem resistance across the human-animal-environmental interface in India. , 2022, Infectious diseases now.

[2]  F. Tenover Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections , 2021, Frontiers in Cellular and Infection Microbiology.

[3]  A. Hamprecht,et al.  Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases , 2021, Antibiotics.

[4]  K. Walia,et al.  Understanding complexities in the uptake of indigenously developed rapid point-of-care diagnostics for containment of antimicrobial resistance in India , 2021, BMJ Global Health.

[5]  G. Hansen Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria , 2021, Infectious Diseases and Therapy.

[6]  P. Nordmann,et al.  Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Mylonakis,et al.  Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department , 2019, PloS one.

[8]  M. Chandy,et al.  Rapid and economical detection of eight carbapenem-resistance genes in Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp directly from positive blood cultures using an internally controlled multiplex-PCR assay , 2019, Infection Control & Hospital Epidemiology.

[9]  S. Essack,et al.  Review of established and innovative detection methods for carbapenemase‐producing Gram‐negative bacteria , 2015, Journal of applied microbiology.

[10]  Gilbert GREUB,et al.  Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  Eoin L. Brodie,et al.  Use of 16S rRNA Gene for Identification of a Broad Range of Clinically Relevant Bacterial Pathogens , 2015, PloS one.

[12]  Y. Glupczynski,et al.  Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. , 2013, The Journal of antimicrobial chemotherapy.